Britain's GW Pharma plans to conduct trials in humans to treat obesity from a drug derived from the plant Cannabis. This was disclosed by Justin Gover, the Managing Director of the company.

As per Mr Gover, there are around seventy cannabinoids in Cannabis plant and each part of the plant has a different effect on human body. While a part of the cannabis plant has the power to curb hunger, some other part of the same plant can rouse hunger. This property is very interesting and beneficial to the drug industry.

Meanwhile GW is also involved in the production of an 'under the tongue' spray called Sativex which is used in the treatment of patients suffering from spasticity due to multiple sclerosis. While this drug is approved in Canada, it is yet to get approved in Britain and other European countries. The company hopes to get this drug cleared in UK around September.